Personal Autonomy as Quality of Life Predictor for Multiple Sclerosis Patients.
Rodica PădureanuCarmen Valeria AlbuIonica PiriciRadu Razvan MititeluMihaela Simona SubtireluRazvan Aurelian Turcu-StiolicaHarri SintonenVlad PadureanuAdina Turcu-StiolicaPublished in: Journal of clinical medicine (2020)
Multiple sclerosis (MS) is a chronic, severe disease, characterized by a progressive alteration in neuronal transmission, which decreases personal independence and quality of life (QoL). This study aimed to investigate the relationship between QoL and personal autonomy in patients with MS, as well as its correlation with age, educational level, and diseases severity. Twenty-six MS patients were followed-up for six months. All patients completed the 15D questionnaire two times: at T0, when they started a new treatment, and at T1 after six months of treatment. At the end point, all patients completed the Personal Autonomy Questionnaire. The average patient age was 43 years (SD = 10), and 89% of them were female. The mean severity and duration of MS were 3.5 (SD = 1.75) and 9.5 (SD = 5.1), respectively. The average QoL of MS patients at T0 was 0.66 (SD = 0.18), and that at T1 was 0.71 (SD = 0.16). The scores of patients with different types of MS, i.e., relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS), were compared. SPMS patients were older than RRMS patients (mean age 47.5 vs. 39.7 years; p = 0.032), and more RRMS patients were working (0.014). SPMS patients described the same QoL and personal autonomy as RRMS patients. Results from bivariate correlation analyses showed a significant relationship between QoL and age, education, and severity of MS. Also, the analysis showed no significant correlation between QoL and personal autonomy.
Keyphrases
- multiple sclerosis
- end stage renal disease
- chronic kidney disease
- ejection fraction
- mass spectrometry
- peritoneal dialysis
- prognostic factors
- healthcare
- ms ms
- brain injury
- systemic lupus erythematosus
- patient reported outcomes
- cross sectional
- white matter
- rheumatoid arthritis
- quality improvement
- disease activity
- blood brain barrier
- subarachnoid hemorrhage
- combination therapy